Sign in
Taking people in GermanyPhase 2

Testing an oral medicine, KT-621, for adults with hard-to-control eosinophilic asthma

Tests KT-621 taken by mouth in adults with uncontrolled eosinophilic asthma.

Key facts

Who runs it
Kymera Therapeutics Inc.
Where
Berlin and Leipzig, GermanySee the 3 sitesAlso in 7 other countries, 39 sites
Registry title
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
Status
Recruiting
Phase
Phase 2
People taking part
121 people, planned
Started
12 May 2026
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 75 with uncontrolled moderate to severe eosinophilic asthma who already use a medium- to high-dose inhaled steroid with a long-acting bronchodilator.

Age
18 to 75 years (or the legal age of consent where the study takes place)
Sex
All sexes
Disease stage
Doctor-diagnosed asthma for at least 52 weeks. Uncontrolled moderate to severe asthma with at least 1 flare-up in the past 52 weeks. Lung function (FEV1) of 40-80% of predicted. ACQ-5 score of at least 1.5.
Earlier treatment
Stable medium- to high-dose inhaled corticosteroid (at least 500 µg fluticasone propionate DPI or equivalent) with a long-acting β2-agonist (LABA). Extra controller medicines are allowed. All used for at least 12 weeks, with no dose change for at least 4 weeks.
Biomarker or test result
Blood eosinophil count of at least 0.30 x 10^9/L. FeNO of at least 25 ppb. Reversible airway narrowing shown by a breathing test after albuterol/salbutamol.

Main reasons for not taking part

  • Other lung disease besides asthma, such as COPD or cystic fibrosis
  • Asthma flare-up in the 4 weeks before screening or up to the baseline visit
  • Current smoker or vaper, or 10 or more pack years of smoking
  • Positive HIV, hepatitis B or hepatitis C test, or tuberculosis infection
  • Cancer in the last 5 years, with a few skin and cervical exceptions

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Documented history of at least 1 asthma exacerbation requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening within the past 52 weeks prior to Screening (V1)
  • Absolute blood eosinophil count must be ≥0.30 x 10^9/L at Screening; up to 2 repeat assessments (3 total) are allowed during the screening period up to the Baseline visit (V2)
  • Male or female assigned at birth, inclusive of all gender identities. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Must be 18 years old (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age, inclusive, at the time of signing the ICF
  • Must have a physician diagnosis of asthma for ≥ 52 weeks prior to the Screening visit (V1), based on the Global Initiative for Asthma (GINA) 2024 guidelines
  • Must be on a stable regimen of medium- to high-dose inhaled corticosteroid (ICS) defined as ≥500 µg fluticasone propionate DPI (or equivalent total daily dose) in combination with a long-acting β2-agonist (LABA). The regimen may include additional controller medication (e.g., leukotriene receptor antagonist [LTRA] and/or long-acting muscarinic antagonist [LAMA]). All background controller medications must have been used for ≥12 weeks prior to Screening (V1) and be at a stable dose and regimen with no change in dose or frequency of administration for ≥4 weeks prior to Screening (V1) and between Screening and Baseline (V2)
  • Morning pre-bronchodilator FEV₁ 40–80% of predicted normal at Screening (V1) and at Baseline (V2), prior to randomization. Up to 2 repeat assessments (3 total) are allowed during the Screening period up to Baseline. If the criterion is not met at Baseline (V2), one additional repeat Baseline visit is permitted within 5 days; at a repeat Baseline visit all baseline assessments must be repeated in full. The qualifying Baseline visit will be used to determine timing of subsequent visits
  • ACQ-5 score ≥ 1.5 at the Screening visit (V1) and at the Baseline visit (V2), prior to randomization
  • Fractional exhaled nitric oxide (FeNO) ≥25 ppb at Screening (V1) and at Baseline (V2). Up to 2 repeat assessments (3 total) are allowed during Screening up to Baseline. If not met at Baseline (V2), one additional repeat Baseline assessment is permitted within 5 days; at a repeat Baseline visit all baseline assessments must be repeated in full
  • Demonstrated evidence of reversible airway obstruction by post-bronchodilator (albuterol/salbutamol) reversibility of FEV₁ at Screening (15–30 minutes after administration of 2–4 puffs of albuterol/salbutamol). Up to 2 repeat assessments (3 total) are allowed during Screening up to Baseline. If applicable, the repeat Baseline allowance described for Criteria 4–6 applies

Who cannot take part

  • Current smokers of nicotine/tobacco as well as non-nicotine products, participants with smoking history of ≥10 pack years, and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of < 10 pack years and users of vaping or e-cigarette products must have stopped for at least 26 weeks prior to the Screening visit (V1)
  • An asthma exacerbation, requiring either treatment with systemic corticosteroids (intramuscular, intravenous, or oral) and/or hospitalization or an emergency/urgent medical care visit for acute asthma worsening, at any time from 4 weeks prior to the Screening visit (V1) up to and including the Baseline visit (V2)
  • Has had any major surgery within 8 weeks prior to the Screening visit (V1) or has any planned surgical or medical procedure planned during the study
  • Has a chronic or acute infection, including upper or lower respiratory tract infection, requiring treatment with systemic antibiotics, antiparasitics, antifungals, or antivirals that were completed within 4 weeks of Baseline or during the Screening period
  • Has any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor's Medical Monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results
  • Has a history of alcohol or drug abuse within 2 years of the Screening visit (V1)
  • Has any cancer or a history of cancers within the last 5 years (except curatively treated with surgical excised squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin or cervix)
  • Has had any of the following at Screening: a. Positive human immunodeficiency virus (HIV) antibody b. Positive hepatitis B (HBV) surface antigen (HBsAg) c. Positive total hepatitis B core antibody (HBcAb) d. Positive hepatitis C virus (HCV) antibody e. Have evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB)
  • Known or suspected history of immunodeficiency disorder, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), despite infection resolution; or unusually frequent, recurrent or prolonged infections, per Investigator's judgment
  • Has a clinically significant history or evidence of any active or suspected parasitic infection within 4 weeks of the Baseline visit (V2) or has travelled within the 3 months before Baseline to areas of high parasitic exposure, as determined by local or international health guidelines or epidemiological data
  • The presence of any clinically significant pulmonary disease other than asthma, including, but not limited to, active lung infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity associated hypoventilation syndrome, lung cancer, alpha 1 antitrypsin deficiency, or primary ciliary dyskinesia. Additionally, any pulmonary or systemic condition other than asthma that is associated with elevated peripheral eosinophil counts, such as allergic bronchopulmonary aspergillosis/mycosis, Churg Strauss syndrome, or hypereosinophilic syndrome
  • Has any of the following findings at the Screening visit (V1): a. Inadequate hematological function, as follows: i. Platelet count < 100 × 10^9/L (< 100,000/µL) ii. Hemoglobin < 9 g/dL iii. Absolute neutrophil count < 1.5 × 10^9/L (< 1,500/µL) b. Inadequate liver function, as follows: i. Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN) ii. Total bilirubin > 1.5 x ULN (participants with Gilbert's syndrome can be included with total bilirubin > 1.5 × ULN) as long as direct bilirubin is ≤ 1.5 x ULN)
  • Has any other clinically significant disease, condition, or medical history that, in the opinion of the Investigator, would interfere with participant safety, study evaluations, and/or study procedures. Examples include, but are not limited to, participants with short life expectancy, participants with uncontrolled diabetes (hemoglobin A1c ≥9%), partecipants with cardiovascular conditions (eg, heart failure, uncontrolled hypertension), severe renal conditions (eg, participants on dialysis), hepatobiliary conditions (eg, Child Pugh class B or C), neurological conditions (eg, demyelinating diseases), active major autoimmune diseases (such as, but not limited to, lupus, inflammatory bowel disease, rheumatoid arthritis), and other severe endocrinological, gastrointestinal, metabolic, pulmonary, or lymphatic diseases

Where in Germany

Also in 7 other countries, 39 sites

  • Lungenpraxis HohenzollerndammBerlin, GermanyTaking people
  • Berufsausuebungsgemeinschaft Bag Prof. Dr. Med Gerhard Hoheisel Dr. Med Andreas Bonitz GbRLeipzig, GermanyTaking people
  • POIS Sachsen GmbHLeipzig, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the efficacy of multiple doses of KT-621 compared to placebo in participants with uncontrolled moderate to severe eosinophilic asthma

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
Plain-language title
Testing an oral medicine, KT-621, for adults with hard-to-control eosinophilic asthmaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 September 2026